EGFR and hypertensive disorder: In general, grade ≥ 3 AEs were more frequent in patients treated with angiogenesis inhibitors and included hypertension (RR 6.41, 95% CI 3.77-10.91, P<0.00001), hemorrhage (RR 2.14, 95% CI 1.07-4.28, P = 0.03) and proteinuria (RR 15.18, 95% CI 2.02-113.88, P= 0.008) for anti-angiogenic-induced events, and neutropenia (RR 7.60, 95% CI 2.50-23.09, P = 0.0003), thrombocytepenia (RR 3.98, 95% CI 1.36-11.63, P = 0.01), diarrhea (RR 5.70, 95% CI 3.50-9.30, P< 0.00001) and fatigue (RR 2.21, 95% CI 1.40-3.51, P = 0.0007) for EGFR-TKIs induced events.